297 related articles for article (PubMed ID: 28883399)
1. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed.
Wipperman MF; Fitzgerald DW; Juste MAJ; Taur Y; Namasivayam S; Sher A; Bean JM; Bucci V; Glickman MS
Sci Rep; 2017 Sep; 7(1):10767. PubMed ID: 28883399
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
Namasivayam S; Maiga M; Yuan W; Thovarai V; Costa DL; Mittereder LR; Wipperman MF; Glickman MS; Dzutsev A; Trinchieri G; Sher A
Microbiome; 2017 Jul; 5(1):71. PubMed ID: 28683818
[TBL] [Abstract][Full Text] [Related]
3. The host microbiome and impact of tuberculosis chemotherapy.
O'Toole RF; Gautam SS
Tuberculosis (Edinb); 2018 Dec; 113():26-29. PubMed ID: 30514510
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs.
Hu Y; Yang Q; Liu B; Dong J; Sun L; Zhu Y; Su H; Yang J; Yang F; Chen X; Jin Q
J Infect; 2019 Apr; 78(4):317-322. PubMed ID: 30107196
[TBL] [Abstract][Full Text] [Related]
5. Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment.
Cao D; Liu W; Lyu N; Li B; Song W; Yang Y; Zhu J; Zhang Z; Zhu B
Microbiol Spectr; 2021 Dec; 9(3):e0061521. PubMed ID: 34908436
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Microbiome-immune interactions in tuberculosis.
Mori G; Morrison M; Blumenthal A
PLoS Pathog; 2021 Apr; 17(4):e1009377. PubMed ID: 33857251
[TBL] [Abstract][Full Text] [Related]
8. The role of microbiota in respiratory health and diseases, particularly in tuberculosis.
Shah T; Shah Z; Baloch Z; Cui X
Biomed Pharmacother; 2021 Nov; 143():112108. PubMed ID: 34560539
[TBL] [Abstract][Full Text] [Related]
9. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?
Eribo OA; du Plessis N; Ozturk M; Guler R; Walzl G; Chegou NN
Cell Mol Life Sci; 2020 Apr; 77(8):1497-1509. PubMed ID: 31729564
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal profiling of gut microbiome among tuberculosis patients under anti-tuberculosis treatment in China: protocol of a prospective cohort study.
Shi W; Hu Y; Zheng X; Ning Z; Wu M; Xia F; Prast-Nielsen S; Hu YOO; Xu B
BMC Pulm Med; 2019 Nov; 19(1):211. PubMed ID: 31711450
[TBL] [Abstract][Full Text] [Related]
11. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
14. Survey on medicinal plants traditionally used in Senegal for the treatment of tuberculosis (TB) and assessment of their antimycobacterial activity.
Diop EA; Queiroz EF; Kicka S; Rudaz S; Diop T; Soldati T; Wolfender JL
J Ethnopharmacol; 2018 Apr; 216():71-78. PubMed ID: 29289797
[TBL] [Abstract][Full Text] [Related]
15. Errors in the treatment of tuberculosis in Baltimore.
Rao SN; Mookerjee AL; Obasanjo OO; Chaisson RE
Chest; 2000 Mar; 117(3):734-7. PubMed ID: 10712999
[TBL] [Abstract][Full Text] [Related]
16. Microbiome Changes during Tuberculosis and Antituberculous Therapy.
Hong BY; Maulén NP; Adami AJ; Granados H; Balcells ME; Cervantes J
Clin Microbiol Rev; 2016 Oct; 29(4):915-26. PubMed ID: 27608937
[TBL] [Abstract][Full Text] [Related]
17. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
[TBL] [Abstract][Full Text] [Related]
18. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
19. Infection caused by Mycobacterium tuberculosis.
Peloquin CA; Berning SE
Ann Pharmacother; 1994 Jan; 28(1):72-84. PubMed ID: 8123968
[TBL] [Abstract][Full Text] [Related]
20. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
